Loading patent…
AssigneeSanorell Pharma GmbH & Co.
InventorsSusanne Koch, Gerhard Becker
Estimating the term…
The invention concerns a process for preparing a pharmaceutical composition of thymus factors which displays immunomodulating and anti-inflammatory properties and is stable during storage. The process comprises the extraction of a homogenized thymus tissue and subsequent repeated ultrafiltration via a filter membrane having an exclusion volume of 30 kD. The resultant first ultrafiltrate is then subjected to a second ultrafiltration process on a membrane having an exclusion volume of 3 kD, the retentate being used. A composition prepared in this way, in contrast to the first ultrafiltrate obtained on leukocyte cultures stimulated by phytohaemagglutinin, displays a great increase in the production of anti-inflammatory IL-10 and a reduction in the formation of inflammation-promoting IL-2 and IFN-gamma.
Process for the production of a pharmaceutical composition of thymus factors with immunomodulating and inflammation-inhibiting properties comprising the extraction of a homogenized thymus tissue by means of an aqueous solution, separating the solid components of the extract, and at least one first ultrafiltration of the extract through a filter membrane with an exclusion volume of 30 kD in order to obtain a first ultrafiltrate, said first ultrafiltrate being subjected to at least one additional second filtration through an ultrafilter with an exclusion volume of 3 kD to form a retentate.
A method of treating a warm-blooded animal having a condition requiring immunomodulating action or anti-inflammatory action, comprising administering to said warm-blooded animal an effective amount of a pharmaceutical composition of thymus factors, said pharmaceutical composition being prepared by the extraction of a homogenized thymus tissue by means of an aqueous solution, separating the solid components of the extract, and at least one first ultrafiltration of the extract through a filter membrane with an exclusion volume of 30 kD in order to obtain a first ultrafiltrate, wherein the first ultrafiltrate is subjected to at least one additional second filtration through an ultrafilter with an exclusion volume of 3 kD to obtain retentate comprising said thymus factors.
Dependencies are inferred from the claim text.